Cystic fibrosis, caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) protein, is a rare and life-limiting genetic disorder that is characterized by thick, sticky mucus and pulmonary complications. The prognosis of patients has improved markedly over recent decades with the advent of new treatments, increasing the mean life expectancy of patients to 37 years. These include inhaled antibiotics for managing chronic lung infections, as well as mucolytics that facilitate the breakdown and clearance of mucus from the lungs, improving airflow and decreasing the risk of infection.

This Datamonitor Healthcare Disease Coverage report contains Forecast, Treatment, Epidemiology, Marketed Drugs, and Pipeline modules.